Manuel Kussmann - Infectious Diseases

Author Information

Manuel Kussmann is a researcher affiliated with the Department of Medicine I, Division of Infectious Diseases and Tropical Medicine at the Medical University Vienna, located in Vienna, Austria. His work primarily revolves around infectious diseases, with a focus on both clinical and laboratory research to address pressing health challenges.

Research Contributions

Manuel Kussmann has made significant contributions to the field of infectious diseases through his diverse range of publications. His research includes the study of treatments and interventions for COVID-19, such as the evaluation of convalescent plasma treatment and immune activation markers during the early onset of infection. Additionally, he has delved into the treatment of other infectious diseases, including Legionellosis and Staphylococcus aureus bloodstream infections. His work extends to investigating the compatibility of medications in specific medical scenarios, such as peritoneal dialysis fluids.

Aliases

Manuel Kussmann may also be referenced in academic and professional settings as M. Kussmann.

Publication and Citation Metrics

Total Citation Count	259
H-index	10
Total Paper Count	28

Publications:

Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis

DOI: 10.3389/fimmu.2022.817829

Year: 2022

Evaluation of Eosinophilic Cationic Protein as a Marker of Alveolar and Cystic Echinococcosis

DOI: 10.3390/pathogens11020261

Year: 2022

In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora

DOI: 10.1136/rmdopen-2021-001737

Year: 2021

A Longitudinal Seroprevalence Study Evaluating Infection Control and Prevention Strategies at a Large Tertiary Care Center with Low COVID-19 Incidence

DOI: 10.3390/ijerph18084201

Year: 2021

Synergistic Effect of Cefazolin Plus Fosfomycin Against Staphylococcus aureus in vitro and in vivo in an Experimental Galleria mellonella Model

DOI: 10.3389/fphar.2021.685807

Year: 2021

Extracellular vesicles and citrullinated histone H 3 in coronavirus disease 2019 (COVID-19) patients.

DOI: 10.1055/a-1522-4131

Year: 2021

Treatment of Legionellosis Including a Single Intravenous Dose of 1.5 g Azithromycin: 18-year Experience at a Tertiary Care Hospital

DOI: 10.1016/j.ijantimicag.2021.106481

Year: 2021

Identification of Immune Activation Markers in the Early Onset of COVID-19 Infection

DOI: 10.3389/fcimb.2021.651484

Year: 2021

Different Types of Coagulase Are Associated With 28-Day Mortality in Patients With Staphylococcus aureus Bloodstream Infections

DOI: 10.3389/fcimb.2020.00236

Year: 2020

Compatibility of aztreonam in four commercial peritoneal dialysis fluids

DOI: 10.1038/s41598-020-58391-y

Year: 2020

How Do Extreme Weather Events Impact Infectious Disease Spread?

What are Natural Killer (NK) Cells?

How Do Human Activities Amplify These Effects?

How is Gene Therapy Applied in Infectious Diseases?

How is COVID-19 Diagnosed?

What is the future of RT-PCR in Infectious Diseases?

What is Quarantine?

Why is RT-PCR important in Infectious Diseases?

What Challenges Do Surveillance Systems Face?

What Are the Treatment Options for Co-Infections?

Partnered Content Networks

Relevant Topics